Solara Active Pharma Sciences Share Price | Solara Active Pharma Sciences Stock Screener
SOLARA
Pharmaceuticals
Share Price NSE
₹545.80
▼
-12.70 (-2.27%)
Share Price BSE
₹546.85
▼
-12.45 (-2.23%)
As of May 27, 2026, the Solara Active Pharma Sciences share price (NSE: SOLARA) is ₹545.80 on NSE and ₹546.85 on BSE, down 2.27% from the previous close, with shares trading between ₹542.35 and ₹566.95, and a 52-week range of ₹425.55–₹697.00.
Check Solara Active Pharma Sciences 52-week for the annual price range and momentum.
Use the Solara Active Pharma Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Solara Active Pharma Sciences Market Cap
₹2,020.25 Cr.
SOLARA P/E Ratio (TTM)
-267.66
Solara Active Pharma Sciences P/B Ratio
1.61
EPS (TTM)
₹-1.68
Dividend Yield
-
Debt to Equity
0.89
SOLARA 52 Week High
₹697.00
Solara Active Pharma Sciences 52 Week Low
₹425.55
Operating Margin
15.00%
Profit Margin
2.54%
SOLARA Revenue (TTM)
₹393.00
EBITDA
₹63.00
Net Income
₹10.00
Total Assets
₹2,333.00
Total Equity
₹1,253.00
Solara Active Pharma Sciences Share Price Chart
Screen Solara Active Pharma Sciences share price with an interactive chart. Analyse SOLARA price trends and volatility across different timeframes.
Solara Active Pharma Sciences Company Profile - Fundamental Screener
Screen Solara Active Pharma Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SOLARA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE624Z01016
Solara Active Pharma Sciences Balance Sheet Screener
Screen SOLARA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 2,333 | 2,232 | 2,351 | 2,899 | 2,945 | 2,614 | 2,154 | 1,960 | 1,822 |
| Current Assets | 858 | 729 | 801 | 1,188 | 1,239 | 1,058 | 672 | 648 | 608 |
| Fixed Assets | 1,077 | 1,193 | 1,268 | 1,364 | 1,356 | 1,382 | 1,397 | 1,218 | 1,086 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 183 | 191 | 172 | 296 | 354 | 232 | 333 | 344 | 315 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 1,253 | 1,097 | 937 | 1,502 | 1,527 | 1,593 | 1,090 | 960 | 769 |
| Share Capital | 45 | 40 | 36 | 36 | 36 | 36 | 27 | 26 | 25 |
| Reserves & Surplus | 1,208 | 1,054 | 898 | 1,464 | 1,489 | 1,553 | 963 | 826 | 739 |
Solara Active Pharma Sciences Income Statement Screener - Profit & Revenue Analysis
Screen Solara Active Pharma Sciences income statement and profit fundamentals.
Analyze SOLARA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Solara Active Pharma Sciences share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 393 | 349 | 314 | 320 | 279 | 302 | 347 | 364 | 301 | 212 | 426 | 354 | 385 | 402 | 342 |
| Expenses | 330 | 318 | 279 | 262 | 228 | 243 | 286 | 322 | 412 | 436 | 393 | 333 | 332 | 350 | 311 |
| EBITDA | 63 | 31 | 35 | 58 | 51 | 59 | 62 | 43 | -111 | -224 | 34 | 21 | 53 | 52 | 31 |
| Operating Profit % | 15.00% | 9.00% | 11.00% | 18.00% | 17.00% | 19.00% | 18.00% | 12.00% | -38.00% | -106.00% | 8.00% | 5.00% | 13.00% | 11.00% | 8.00% |
| Depreciation | 26 | 26 | 25 | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 26 | 26 | 27 | 28 | 29 |
| Interest | 28 | 23 | 21 | 24 | 29 | 27 | 28 | 31 | 31 | 25 | 24 | 25 | 22 | 24 | 22 |
| Profit Before Tax | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -14 | -167 | -275 | -17 | -29 | 5 | 1 | -19 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89 | 0 | 0 | -10 | 1 | 0 | -9 |
| Net Profit | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -14 | -255 | -275 | -17 | -19 | 4 | 0 | -10 |
| EPS | 2.20 | -3.98 | -2.36 | 2.46 | -0.93 | 2.03 | 2.54 | -3.50 | -70.93 | -72.07 | -4.77 | -5.43 | 1.05 | 0.12 | -2.77 |
Solara Active Pharma Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SOLARA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 213 | 109 | 156 | -242 | 156 | 242 | 166 | 49 |
| Investing Activities | -37 | -4 | -81 | -243 | -106 | -359 | -113 | -86 |
| Financing Activities | -181 | -106 | -113 | 334 | 93 | 97 | -23 | 68 |
| Net Cash Flow | -5 | 0 | -38 | -151 | 142 | -20 | 30 | 32 |
Solara Active Pharma Sciences Shareholding Pattern Screener
See Solara Active Pharma Sciences shareholding pattern with promoter, FII, and DII holdings.
Check Solara Active Pharma Sciences promoter holding and ownership changes for SOLARA on TickJournal.
| Item | 2026-May | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 42.00% | 42.00% | 42.00% | 42.01% | 42.01% | 37.94% | 37.23% | 37.27% |
| FII Holding | 11.33% | 11.59% | 11.98% | 13.58% | 14.25% | 14.63% | 14.67% | 14.25% |
| DII Holding | 3.78% | 3.75% | 3.64% | 2.69% | 2.62% | 2.61% | 3.19% | 3.38% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 25.15% | 25.03% | 24.63% | 24.01% | 23.47% | 23.07% | 21.93% | 18.83% |
| Other Holding | 17.74% | 17.63% | 17.74% | 17.70% | 17.63% | 21.74% | 22.98% | 26.28% |
| Shareholder Count | 70,037 | 70,400 | 71,920 | 72,479 | 74,334 | 75,791 | 83,148 | 71,882 |
Solara Active Pharma Sciences Share Dividend Screener - Share Yield Analysis
Check Solara Active Pharma Sciences dividend history with payout and yield data.
View Solara Active Pharma Sciences dividend details including ex-dates and amounts for SOLARA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹3.00 | 0.88% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹7.00 | 1.14% |
| 2020-March | ₹2.00 | 0.16% |
| 2019-March | ₹5.00 | 1.22% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Solara Active Pharma Sciences Stock Index Membership
See which indices include Solara Active Pharma Sciences stock.
Check SOLARA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
Solara Active Pharma Sciences Market Events Screener - Corporate Actions
Get Solara Active Pharma Sciences corporate actions including splits, bonuses, and buybacks.
Check Solara Active Pharma Sciences stock events that may affect SOLARA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 6.04% | ||
| Annual General Meeting | NA | 1.99% | ||
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | -1.55% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 3.68% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 4.97% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -5.15% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 19.48% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.29% |
| 2024-10-21 | 2024-10-21 | Quarterly Result Announcement | NA | 8.18% |
| 2024-05-15 | 2024-05-15 | Rights | 1:3 | 8.26% |
| 2021-08-18 | 2021-08-20 | Dividend | ₹ 3.00 /share | 5.36% |
| 2017-03-25 | 2017-03-25 | Change Of Name | NA | - |
Solara Active Pharma Sciences Competitors Screener - Peer Comparison
Screen SOLARA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,670 | 40.42 | 58,220 | 6.38% | 11,565 | 54.06 |
| Divis Laboratories | 179,271 | 73.73 | 10,560 | 8.73% | 2,520 | 57.07 |
| Torrent Pharmaceuticals | 150,679 | 66.80 | 13,753 | 19.18% | 2,028 | 56.43 |
| Cipla | 114,503 | 29.26 | 27,712 | -2.46% | 3,783 | 64.74 |
| Dr Reddys Laboratories | 110,832 | 26.24 | 33,593 | -0.44% | 3,998 | 56.54 |
| Zydus Life Science | 108,578 | 20.40 | 26,720 | 13.65% | 5,242 | 74.62 |
| Lupin | 103,566 | 19.46 | 27,488 | 19.98% | 5,345 | 45.18 |
| Mankind Pharma | 100,047 | 52.84 | 14,278 | 12.03% | 1,750 | 55.67 |
| Aurobindo Pharma | 84,867 | 24.29 | 33,385 | 3.21% | 3,376 | 52.40 |
| Laurus Labs | 74,171 | 81.46 | 6,813 | 21.03% | 884 | 80.00 |
Solara Active Pharma Sciences Company Announcements - News Screener
Screen SOLARA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-05-15 | Intimation Regarding The Adoption Or Amendments Of Policies | - |
| 2026-05-15 | Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended March 31 2026. | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-05-15 | Intimation Regarding The Reappointment Of Cost Auditor And Internal Auditor | - |
| 2026-05-15 | Intimation In Relation To The Rights Issue | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-15 | Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-15 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Year Ended March 31 2026 And Unaudited Financial Results For The Quarter Ended March 31 2026. | - |
| 2026-05-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-08 | Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) | - |
| 2026-04-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-07 | Intimation Regarding Dispatch Of The Second And Final Call Money Notice Of The Rights Equity Shares. | - |
| 2026-03-26 | Closure of Trading Window | - |